Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

REVEALED: Looking into royalty pharma s return on capital employed - The Real Truth

According to Benzinga Pro, during Q4, Royalty Pharma (NASDAQ:RPRX) earned $53.67 million, a 75.8% increase from the preceding quarter. Royalty Pharma's sales decreased to $576.00 million, a 1.67% change since Q3. In Q3, Royalty Pharma earned $221.80 million, and total sales reached $585.77 million.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.